Progression-free Survival
Fig. 2 · Panel A
Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Yang Sun, Hongying Yang, Jing Wang, Hanmei Lou, Dan Li, Ke Wang, Hui Zhang, Tao Wu, Yuzhi Li, Chunyan Wang, Guiling Li, Yifeng Wang, Dapeng Li, Ying Tang, Mei Pan, Hongyi Cai, Weihu Wang, Bing Yang, Hua Qian, Qiuhong Tian, Desheng Yao, Ying Cheng, Bing Wei, Xiumin Li, Tao Wang, Min Hao, Xiaohong Wang, Tiejun Wang, Chang Liu, Hong Zhu, Lijing Zhu, Xianling Liu, Yunxia Li, Lihong Chen, Qingshan Li, Xiaojian Yan, Fei Wang, Hongbing Cai, Yunyan Zhang, Zhiqing Liang, Funan Liu, Yi Huang, Bairong Xia, Pengpeng Qu, Genhai Zhu, Youguo Chen, Kun Song, Meili Sun, Zhengzheng Chen, Qiang Zhou, Lina Hu, Guzhalinuer Abulizi, Hongyan Guo, Sihai Liao, Yijing Ye, Ping Yan, Qiu Tang, Guoping Sun, Ting Liu, Dongmei Lu, Mingxiu Hu, Zhongmin M Wang, Baiyong Li, Michelle Xia, Xiaohua Wu
Nat Commun 17(1) 3931
The phase 3 COMPASSION-16 trial demonstrates significant progression-free survival (PFS) and overall survival (OS) benefits with cadonilimab plus standard therapy in patients with persistent, recurrent, or metastatic cervical cancer. This analysis aims to assess efficacy outcomes in patient subgroups of COMPASSION-16. The dual primary endpoints of COMPASSION-16 are PFS, assessed by the blinded independent central review (BICR) according to RECIST version 1.1, and OS. The secondary endpoint is objective response rate. In this subgroup analysis, the PFS, OS and objective response rate are evaluated in subgroups including bevacizumab use, prior concurrent chemoradiotherapy, PD-L1 combined positive score (CPS), metastatic disease at baseline, platinum use, and age. With median follow-up of 25.6 months, hazard ratios (HRs) for PFS favour cadonilimab group in all subgroups. Moreover, the addition of cadonilimab is also associated with prolonged overall survival. This subgroup analysis confirms that improvements in progression-free and overall survival are consistent with the primary results of the COMPASSION-16 study across diverse patient profiles.
6 个 Figure · 13 个 KM 面板
Fig. 2. Progression-free survival by bevacizumab use. Kaplan–Meier estimate in subgroups with bevacizumab use ( A ) and without bevacizumab use ( B ), and subgroup analysis ( C ). Source data are provided as a Source data file.
Fig. 2 · Panel A
Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 2 · Panel B
Panel B 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3. Progression-free survival by prior concurrent chemoradiotherapy (CCRT). Kaplan–Meier estimate in subgroups with prior CCRT ( A ) and without prior CCRT ( B ), and subgroup analysis ( C ). Source data are provided as a Source data file.
Fig. 3 · Panel A
Panel A 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel B
Panel B 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4. Progression-free survival by PD-L1 expression. Kaplan–Meier estimate in subgroups of PD-L1 CPS1 ( A ), PD-L1 CPS≥1 ( B ), PD-L1 CPS≥10 ( C ), and subgroup analysis ( D ). Source data are provided as a Source data file.
Fig. 4 · Panel A
Panel A 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel B
Panel B 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel C
Panel C 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 5. Progression-free survival by metastatic disease at baseline. Kaplan–Meier estimate in subgroups with metastatic disease ( A ) and without metastatic disease ( B ), and subgroup analysis ( C ). Source data are provided as a Source data file.
Fig. 5 · Panel A
Panel A 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 5 · Panel B
Panel B 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 6. Progression-free survival by choice of platinum therapy. Kaplan–Meier estimate in subgroups with cisplatin ( A ) and with carboplatin ( B ), and subgroup analysis ( C ). Source data are provided as a Source data file.
Fig. 6 · Panel A
Panel A 是同一 Fig. 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 6 · Panel B
Panel B 是同一 Fig. 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 7. Progression-free survival by age. Kaplan–Meier estimate in subgroups aged 65 years ( A ) and ≥65 years ( B ), and subgroup analysis ( C ). Source data are provided as a Source data file.
Fig. 7 · Panel A
Panel A 是同一 Fig. 7 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 7 · Panel B
Panel B 是同一 Fig. 7 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。